MARKET

CNTG

CNTG

CENTOGENE B.V.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.96
-0.37
-3.27%
Opening 12:20 09/21 EDT
OPEN
11.30
PREV CLOSE
11.33
HIGH
11.67
LOW
10.83
VOLUME
20.79K
TURNOVER
--
52 WEEK HIGH
28.71
52 WEEK LOW
7.80
MARKET CAP
239.60M
P/E (TTM)
-8.1681
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
CENTOGENE to Report First Half 2020 Financial Results on September 23, 2020
CAMBRIDGE, Mass., and ROSTOCK, Germany & BERLIN, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies
GlobeNewswire · 5d ago
CENTOGENE Expands COVID-19 Testing Capacity at Frankfurt Airport
* CENTOGENE has opened an expanded sampling area, next to the existing Walk-In COVID-19 Testing Facility, allowing significant increases in COVID-19 testing sampling capacity * Innovative digital solutions continue to support the fight against the novel coronavirus with a customer-friendly testing experienceCAMBRIDGE
GlobeNewswire · 09/10 13:15
CENTOGENE Expands Coronavirus Testing Capacity At Frankfurt Airport
CENTOGENE Expands COVID-19 Testing Capacity at Frankfurt Airport CENTOGENE has opened an expanded sampling area, next to the existing Walk-In COVID-19 Testing Facility, allowing significant increases in COVID-19
Benzinga · 09/10 12:24
CENTOGENE Publishes Huge Dataset That Supports Genome Sequencing as a First-Line Diagnostic Test
* Publication demonstrates genome sequencing as the optimal standard for genetic testing * Study presents the largest cohort of its kind with over 1,000 index cases * Genome sequencing minimizes stepwise testing, thereby accelerating diagnosis for rare disease patientsCAMBRIDGE, Mass. and ROSTOCK
GlobeNewswire · 09/03 10:30
CENTOGENEs COVID-19 Testing Numbers Represent Rapid Solution for Major German Airports
* CENTOGENE has recently opened coronavirus walk-in test centers at Frankfurt and Hamburg Airport, two of Germany’s largest airports * Over 97% of COVID-19 test reports were processed within 24 hours in August 2020 – offering security and peace of mind to travelers * The combination of electronic workflows
GlobeNewswire · 09/01 13:30
Centogene and Evotec expand collaboration into Gaucher disease
Centogene (CNTG) and Evotec (EVOTF) have expanded their existing drug discovery partnership related to Gaucher disease – a genetic lysosomal storage disorder caused by mutations in the glucocerebrosidase gene. The
Seekingalpha · 08/20 07:11
CENTOGENE and Evotec Expand Collaboration Into Gaucher Disease
GlobeNewswire · 08/20 06:30
CENTOGENE Opens Walk-In COVID-19 Testing Facility at Hamburg Airport
CENTOGENE’s CentoTruck A mobile testing solution for COVID-19 CENTOGENE COVID-19 Testing Facility at Hamburg Airport, Germany CENTOGENE staff ready for passengers at walk-in COVID-19 test facility at Hamburg Airport CENTOGENE COVID-19 Testing Facility at Hamburg Airport, Germany CENTOGENE staff ready
GlobeNewswire · 08/19 06:00
More
No Data
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CNTG stock price target is 22.59 with a high estimate of 25.10 and a low estimate of 21.09.
EPS
Institutional Holdings
Institutions: 31
Institutional Holdings: 1.34M
% Owned: 6.14%
Shares Outstanding: 21.86M
TypeInstitutionsShares
Increased
11
114.33K
New
10
83.97K
Decreased
8
514.64K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.43%
Pharmaceuticals & Medical Research
-2.97%
Key Executives
Chairman - Supervisory/Director
Flemming Ornskov
Chief Executive Officer/Management Board
Arndt Rolfs
Vice Chairman - Supervisory/Independent Director
Peer Schatz
Chief Financial Officer/Management Board
Richard Stoffelen
Chief Operating Officer/Management Board
Dirk Ehlers
Chief Information Officer/Management Board
Volkmar Weckesser
Chief Scientific Officer
Philip Lambert
Director of Investor Relations
Sun Kim
Other
Oved Amitay
Other
Peter Bauer
Independent Director/Supervisory Board
Hubert Birner
Independent Director/Supervisory Board
Berndt Modig
Independent Director/Supervisory Board
Guido Prehn
Independent Director/Supervisory Board
Eric Souetre
Supervisory Board
Christoph Ehlers
Supervisory Board
Holger Friedrich
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average CNTG stock price target is 22.59 with a high estimate of 25.10 and a low estimate of 21.09.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CNTG
Centogene BV is a Germany-based company engaged in the rare disease market. It focuses on transforming clinical, genetic and biochemical data into medical solutions for patients, physicians and pharmaceutical companies. The Company provides the full spectrum of methods and technology for human genetics analysis. It develops a rare disease platform based on its real-world data repository with over 2.0 billion weighted data points from over 450,000 patients representing around 115 different, which includes epidemiologic, phenotypic and genetic data that reflects a global population, as well as a biobank of patients’ blood samples. In addition, it is active in the research and development products for human genetics. The Company operates in Germany and the United States.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Centogene NV stock information, including NASDAQ:CNTG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNTG stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CNTG stock methods without spending real money on the virtual paper trading platform.